Ma et al. [148] and Liu et al. [149] both demonstrated that combining PD-L1 mAb–tMBs with chemotherapeutic drugs or loading PD-L1 mAb–tMBs with genes exhibited strong synergistic effects in inhibiting cervical tumor growth, improving survival rates, and reducing side effects compared to using either drug/gene or PD-L1 mAb–tMBs alone. Here, CD274 is linked to uterine cervix neoplasm.